BPG is committed to discovery and dissemination of knowledge
Featured Articles
10/10/2023 9:20:03 AM | Browse: 441 | Download: 1136
 |
Received |
|
2023-07-21 20:38 |
|
Peer-Review Started |
|
2023-07-21 20:40 |
|
First Decision by Editorial Office Director |
|
2023-08-23 03:02 |
|
Return for Revision |
|
2023-08-23 03:02 |
|
Revised |
|
2023-09-06 15:24 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-09-18 02:39 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-09-18 22:24 |
|
Articles in Press |
|
2023-09-18 22:24 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-10-06 13:39 |
|
Publish the Manuscript Online |
|
2023-10-10 08:15 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Blake Buzard, Lindsey Douglass, Beth Gustafson, Jennifer Buckley, Marc Roth, Lara Kujtan and Dhruv Bansal |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Lara Kujtan, MD, Associate Professor, Department of Medical Oncology, University of Missouri - Kansas City, No. 2310 Holmes St, Kansas, MO 64108, United States. kujtanl@umsystem.edu |
| Key Words |
Colorectal cancer; Osimertinib; Epidermal growth factor receptor T790M; Precision oncology; Tyrosine kinase inhibitor; Case report |
| Core Tip |
Somatic epidermal growth factor receptor (EGFR) mutations are rarely found in colorectal cancer. Treatment with anti-EGFR antibodies is commonplace, but EGFR tyrosine kinase inhibitors are not standard in colorectal cancer. Here we report a case of sustained response to osimertinib in a metastatic colorectal cancer patient with an EGFR T790M mutation detected with cell-free DNA. She progressed on three lines of treatment, and received fourth-line treatment with off-label osimertinib, with clinical response. She received treatment with osimertinib for seven months. This case shows the benefit of multi-gene sequencing assays to identify potential therapeutic options in patients with refractory disease. |
| Publish Date |
2023-10-10 08:15 |
| Citation |
Buzard B, Douglass L, Gustafson B, Buckley J, Roth M, Kujtan L, Bansal D. Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report. World J Gastrointest Oncol 2023; 15(10): 1829-1834
|
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i10/1829.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i10.1829 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
